Ligand Pharmaceuticals reported $1.15M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
Amgen USD 694M 29M Jun/2025
Arrowhead Research USD 24.38M 2.74M Jun/2025
Baxter International USD 81M 19M Mar/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
GlaxoSmithKline 184M 22M Jun/2025
Glaxosmithkline 184M 5.95M Jun/2025
Insmed USD 21.24M 1.5M Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
Ligand Pharmaceuticals USD 1.15M 286K Jun/2025
MacroGenics USD 802K 826K Jun/2025
Merck USD 305M 8M Jun/2025
Pacira USD 3.82M 110K Jun/2025
Pfizer USD 654M 0 Jun/2025
Veracyte USD 0 0 Mar/2025